このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Stepped-Care Support for Children With Leukaemia (STEP-Leukemia)

2026年5月13日 更新者:Fath Ur Rahman、Zhengzhou University

Developing a Stepped-Care Intervention for Emotional and Behavioral Health in Children With Leukemia: A Study Protocol

This study aims to develop, culturally adapt, and pilot test a stepped-care psychosocial intervention designed to improve emotional and behavioral health among children with leukemia in Pakistan. Children with leukemia may experience anxiety, depressive symptoms, irritability, sleep disturbance, social withdrawal, treatment-related distress, and behavioral difficulties during the cancer treatment pathway. In resource-constrained settings, structured psychosocial care is often limited or unavailable within routine pediatric oncology services. This study addresses this gap by developing a feasible, culturally responsive, and theory-informed intervention that can be delivered within existing clinical resources.

The study follows a multi-stage intervention-development process guided by the Intervention Mapping framework and Medical Research Council guidance for complex interventions. The stages include: evidence review and expert consultation to identify gaps in current psychosocial care; mixed-methods needs assessment with children, caregivers, and healthcare professionals; refinement of the intervention through focus groups and an e-Delphi process; and pilot testing of the intervention in a two-arm pilot randomized controlled trial.

The pilot trial will include children aged 7 to 14 years with leukemia who are clinically stable and in the remission or maintenance phase of treatment, together with their primary caregivers. Participants will be allocated to either the stepped-care intervention plus routine care or routine care alone. The stepped-care program is delivered over 12 weeks and progresses from low-intensity universal support to more intensive individualized care according to child and family needs. Intervention components include an information booklet, psychoeducational video, face-to-face psychoeducation, peer support, cognitive behavioral strategies, parent-child behavioral training, and one-to-one therapy or referral when indicated. The intervention will be delivered by trained mental health nurses under supervision of a psychologist.

The primary focus of this pilot trial is feasibility and acceptability, including recruitment, retention, attendance, intervention fidelity, completion of outcome measures, and participant satisfaction. Secondary exploratory outcomes include emotional and behavioral functioning, distress, quality of life, depressive symptoms, sleep disturbance, treatment adherence, and family functioning. Findings will guide refinement of the intervention and inform the design of a future fully powered randomized controlled trial.

調査の概要

状態

招待による登録

詳細な説明

This study will develop, culturally adapt, and pilot evaluate a stepped-care psychosocial intervention to support emotional and behavioural health among children with leukaemia in Pakistan. Children undergoing treatment for leukaemia may experience anxiety, low mood, procedural fear, irritability, sleep disturbance, social withdrawal, school disruption, reduced quality of life, and difficulties with treatment routines. These challenges may also interact with caregiver distress and family functioning. In Pakistan and similar resource-constrained settings, paediatric oncology care is primarily focused on diagnosis, chemotherapy, and medical follow-up, while structured psychosocial screening and evidence-based psychological support are not routinely integrated into care. A culturally adapted stepped-care model may provide a practical approach by offering low-intensity support to all families and reserving more intensive psychosocial input for children and caregivers with greater or persistent needs.

The study is guided by Intervention Mapping and the Medical Research Council guidance for developing and evaluating complex interventions. A sequential, stage-based design will be used, with findings from each stage informing the next stage. The intervention-development process will include evidence synthesis, stakeholder consultation, mixed-methods needs assessment, intervention refinement, and pilot evaluation.

In the first stage, a scoping review and expert consultation will be conducted to identify existing evidence, contextual gaps, feasible intervention components, and implementation considerations relevant to paediatric oncology settings in Pakistan. In the second stage, a mixed-methods needs assessment will explore the emotional, behavioural, family, and service-related needs of children with leukaemia and their caregivers, as well as professional perspectives on feasible psychosocial care delivery. In the third stage, the draft intervention will be refined through feedback from children, caregivers, and multidisciplinary experts, including focus groups and a structured e-Delphi process. This stage will focus on cultural appropriateness, developmental suitability, session burden, delivery format, safety procedures, and stepped-care decision rules.

The final stage will pilot and evaluate the 12-week stepped-care intervention in comparison with routine care. The pilot evaluation is intended to assess feasibility, acceptability, implementation procedures, intervention fidelity, safety, and the suitability of outcome assessment procedures. It is not designed to establish definitive intervention effectiveness. Findings will be used to refine the intervention manual, delivery procedures, and future trial methods.

The stepped-care intervention is designed as a manualised psychosocial programme delivered by trained mental health nurses under psychologist supervision. The intervention includes universal psychoeducation for all participating families, followed by progressively more intensive components according to the child's and caregiver's level of need. Lower-intensity components include an information booklet, psychoeducational video, and face-to-face psychoeducation. Children and families with emerging or persistent psychosocial concerns may receive peer support, cognitive behavioural strategies, parent-child behavioural training, or one-to-one therapeutic support with referral to specialist services when clinically indicated.

The intervention is informed by the stepped-care model, cognitive behavioural theory, stress and coping theory, resilience theory, family systems theory, the social ecological model, and self-regulation theory. Together, these frameworks support the development of an intervention that addresses illness-related appraisal, coping skills, emotional regulation, family communication, social support, behavioural adjustment, and appropriate escalation of care.

Fidelity will be supported through a structured intervention manual, facilitator training, session checklists, intervention logs, and supervision meetings. Safety procedures will be used to identify and refer participants requiring urgent psychological or psychiatric care. Quantitative and qualitative findings from the pilot evaluation will be integrated to determine whether the intervention is feasible, acceptable, culturally appropriate, and suitable for refinement before a future fully powered randomized controlled trial.

研究の種類

介入

入学 (推定)

96

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Khyber Pukhtoon Khwa
      • Peshawar、Khyber Pukhtoon Khwa、パキスタン、25000
        • Hayatabad Medical Complex

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Children diagnosed with leukaemia (confirmed by medical records).
  • Aged between 7 and 14 years at the time of diagnosis.
  • Primary carers (parents, guardians, or immediate family members) who are directly involved in the child's care and treatment.
  • Ability to comprehend and communicate in the local language (e.g., Urdu, Pashto).
  • Child in the stable remission or maintenance phase of leukaemia treatment.
  • Willingness to participate in the study and provide informed consent (child assent and parental consent).

Exclusion Criteria:

  • Acute medical instability requiring intensive care.
  • Cognitive impairment preventing meaningful participation.
  • Severe mental health conditions (e.g., active psychosis, extreme depression) in the child.
  • Non-primary carers without direct responsibility for the child's care.
  • Active substance abuse or impairing conditions in the primary carer.
  • Non-English/non-Urdu/Pashto-speaking participants.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intervention Group
Step Care Intervention Participants will receive a 12-week stepped-care psychosocial intervention including psychoeducation, peer support, CBT sessions, parent-child training, and individualised therapy along with routine care.
Participants will receive a 12-week stepped-care psychosocial intervention including psychoeducation, peer support, CBT sessions, parent-child training, and individualized therapy along with routine care
介入なし:Control Group
Routine Care and Treatment

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Strengths and Difficulties Questionnaire Total Difficulties Score From Baseline to 12 Weeks
時間枠:Baseline and 12 weeks

Child emotional and behavioural difficulties will be assessed using the Strengths and Difficulties Questionnaire total difficulties score. The total difficulties score is calculated from the emotional symptoms, conduct problems, hyperactivity/inattention, and peer relationship problems subscales. Scores range from 0 to 40. Higher scores indicate greater emotional and behavioural difficulties. Unit of Measure:

Score on a scale

Score Range:

0 to 40

Direction:

Higher scores indicate greater emotional and behavioural difficulties.

Baseline and 12 weeks
Change in Paediatric Quality of Life Inventory Total Score From Baseline to 12 Weeks
時間枠:Baseline and 12 weeks

Child health-related quality of life will be assessed using the Paediatric Quality of Life Inventory. Scores are transformed to a 0-100 scale. Higher scores indicate better health-related quality of life. Unit of Measure:

Score on a scale

Score Range:

0 to 100

Direction:

Higher scores indicate better health-related quality of life.

Baseline and 12 weeks
Change in Patient Health Questionnaire-9 Total Score From Baseline to 12 Weeks
時間枠:Baseline and 12 weeks

Caregiver depressive symptoms will be assessed using the Patient Health Questionnaire-9. The PHQ-9 total score ranges from 0 to 27. Higher scores indicate greater severity of depressive symptoms. Unit of Measure:

Score on a scale

Score Range:

0 to 27

Direction:

Higher scores indicate greater depressive symptom severity

Baseline and 12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Pediatric/Procedural Anxiety Distress Thermometer Score From Baseline to 12 Weeks
時間枠:Baseline and 12 weeks

Child procedural anxiety and distress will be assessed using the Paediatric/Procedural Anxiety Distress Thermometer. The score ranges from 0 to 10, with higher scores indicating greater anxiety or distress. Paediatric distress thermometer ratings commonly use a 0 to 10 scale, where 0 indicates no distress and 10 indicates high or extreme distress. Unit of Measure:

Score on a scale

Score Range:

0 to 10

Direction:

Higher scores indicate greater anxiety or distress.

Baseline and 12 weeks
Change in Sleep Disturbance Scale for Children Total Score From Baseline to 12 Weeks
時間枠:Baseline and 12 weeks

Child sleep disturbance will be assessed using the Sleep Disturbance Scale for Children. The scale includes 26 items rated on a 5-point Likert scale. The total score ranges from 26 to 130, with higher scores indicating greater sleep disturbance. Unit of Measure:

Score on a scale

Score Range:

26 to 130

Direction:

Higher scores indicate greater sleep disturbance.

Baseline and 12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年6月10日

一次修了 (実際)

2026年3月30日

研究の完了 (推定)

2026年12月30日

試験登録日

最初に提出

2026年4月16日

QC基準を満たした最初の提出物

2026年5月7日

最初の投稿 (実際)

2026年5月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月18日

QC基準を満たした最後の更新が送信されました

2026年5月13日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • LeukemiaProtocol_2026_001
  • ZZUIRB2025-03 (その他の識別子:Zhengzhou University)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Data sharing will be subject to institutional ethics approval, participant confidentiality requirements, and a signed data-sharing agreement. No personally identifiable information will be shared.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する